WO2003032988A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
WO2003032988A1
WO2003032988A1 PCT/JP2002/010707 JP0210707W WO03032988A1 WO 2003032988 A1 WO2003032988 A1 WO 2003032988A1 JP 0210707 W JP0210707 W JP 0210707W WO 03032988 A1 WO03032988 A1 WO 03032988A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
pharmaceutical composition
halogeno
general formula
compound represented
Prior art date
Application number
PCT/JP2002/010707
Other languages
French (fr)
Japanese (ja)
Inventor
Tomoyuki Shibata
Shinichi Kurakata
Naomi Shimazaki
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of WO2003032988A1 publication Critical patent/WO2003032988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A pharmaceutical composition for administering a compound represented by the general formula (I) or the like and a compound represented by the general formula (II) either simultaneously or separately at a time interval: (I) (II) wherein X is a benzimidazole ring group; Y1 is oxygen or sulfur; Z is a thiazolidinedione group or the like; R is hydrogen, C1-6 alkyl, or the like; m is an integer of 1 to 5; Ra is bromo or iodo; Rb is hydrogen, halogeno, or the like; Rc is -NRkORl [wherein Rk is hydrogen or the like; and Rl is C3-10 cycloalkyl or the like]; and Rd, Re and Rf are each independently hydrogen, halogeno, or the like.
PCT/JP2002/010707 2001-10-17 2002-10-16 Pharmaceutical composition WO2003032988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-319631 2001-10-17
JP2001319631 2001-10-17

Publications (1)

Publication Number Publication Date
WO2003032988A1 true WO2003032988A1 (en) 2003-04-24

Family

ID=19137153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010707 WO2003032988A1 (en) 2001-10-17 2002-10-16 Pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2003032988A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
AU2007213028B2 (en) * 2006-02-09 2010-10-28 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025598A2 (en) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
EP1022272A1 (en) * 1997-10-08 2000-07-26 Sankyo Company Limited Substituted fused heterocyclic compounds
WO2000061581A1 (en) * 1999-04-07 2000-10-19 Sankyo Company, Limited Amine derivatives
JP2000351779A (en) * 1999-04-07 2000-12-19 Sankyo Co Ltd Amine derivative compound

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025598A2 (en) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
EP1022272A1 (en) * 1997-10-08 2000-07-26 Sankyo Company Limited Substituted fused heterocyclic compounds
WO2000061581A1 (en) * 1999-04-07 2000-10-19 Sankyo Company, Limited Amine derivatives
JP2000351779A (en) * 1999-04-07 2000-12-19 Sankyo Co Ltd Amine derivative compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAMP HEIDI S. ET AL.: "Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 16, 1997, pages 10811 - 10816, XP002961077 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007213028B2 (en) * 2006-02-09 2010-10-28 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
AU2007213028C1 (en) * 2006-02-09 2011-05-19 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
US8263631B2 (en) 2006-02-09 2012-09-11 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer

Similar Documents

Publication Publication Date Title
CA2477839A1 (en) Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003033493A1 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
EP1669352A4 (en) Thiazoline derivative and use of the same
EP0894797A4 (en) Novel amide derivatives and intermediates for the synthesis thereof
WO2002100812A1 (en) Carboxylic acid derivative and salt thereof
EP1510516A4 (en) Pyrazole compound and medicinal composition containing the same
EP1780209A4 (en) Oxime ester compound and photopolymerization initiator containing such compound
HUP0302153A2 (en) Piperidine derivetives as modulators of chemokine receptor activity, process for producing them and pharmaceutical compositions containing them
EP1396493A4 (en) Heterocyclic compounds
EP1582521A4 (en) Fused furan compound
EP1813270A4 (en) Hsp90 family protein inhibitors
EP1602647A4 (en) Novel compound having 4-pyridylalkylthio group as substituent
NO20040881L (en) Oral antidiabetic agents.
EP1284266A4 (en) Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
WO2003024953A1 (en) Propanolamine derivative having 1,4-benzodioxane ring
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
WO2004099145A3 (en) Phenyl substituted cyclic derivatives
WO2001012202A3 (en) Use of chemical chelators as reversal agents for drug-induced neuromuscular block
PL370362A1 (en) 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
CA2226886A1 (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
WO2003031414A1 (en) Novel heterocyclic compound and anti-inflammatory agent
WO2003033506A1 (en) Aminoborane acid derivative and proteasome inhibitory drug containing the same
WO2003032988A1 (en) Pharmaceutical composition
EP1550651A4 (en) Glycerol derivative
EP1391452A4 (en) 4-hydroxpiperidine derivative with analgetic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP